Web Exclusives

A paper by Hernandez and colleagues recently published in the Journal of Arthroplasty blames the Medicare 3-day rule for lengthier hospital stays among some patients with total knee arthroplasty (TKA) compared with others. Read More ›

Countdown to ICD-10 Implementation Well Under Way
Stakeholders in the healthcare system are making an effort to ensure that people are not squeezed out of the practice of medicine by insufficient time and support to comply with ICD-10. Read More ›

Prescription Drug Cost Sharing Parsed by Panel at Pharmacoeconomics Meeting
How can the high cost of healthcare be spread among all stakeholders to produce the biggest patient-care bang for the buck? Read More ›

Seven Steps to Finding the Right Financial Advisor
As a physician with substantial income (or income potential), you will most likely be contacted by a number of individuals offering various types of financial products and services throughout your career. Read More ›

Despite substantially higher costs, specialty drugs can offer value comparable with that of traditional medications under certain circumstances, according to a recent cost-effectiveness analysis covering 12 years of FDA drug approvals. Read More ›

Electronic medical records represent unfulfilled promise for identifying patients who are at elevated risk for osteoporosis and fragility fractures, according to a survey of the situation in Ontario, Canada. Read More ›

If your rheumatology practice is physician owned, I am willing to bet that staying independent is very important to both the doctors and managers. In short, you do not want to “work for the man” that runs the health system, hospital, or multispecialty group down the street. Read More ›

Attended by a plurality of the membership, the 12th annual meeting of the Tennessee Rheumatology Society (TRS) fulfilled the society’s stated mission of increasing and propagating the understanding of rheumatic diseases among physicians engaged in the ongoing practice of rheumatology. Read More ›

Mechanism of Pathway: The Promise of PD-1 Pathway Blockade in the Treatment of Metastatic Cancer
Over the years, it has become increasingly evident that cancer is a highly heterogeneous disorder. There are a multitude of different tumor types that can affect all organs and organ systems of the body. Because of genetic variations, no 2 tumors are exactly the same. Read More ›

Page 3 of 3

Subscribe to
Rheumatology Practice Management

Stay up to date with rheumatology news & updates by subscribing to receive the free RPM print publications or weekly e‑Newsletter.

I'd like to receive: